首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >98%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TSLP |
| Uniprot No | Q969D9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 29-159aa |
| 氨基酸序列 | M+ YDFTNCDFE KIKAAYLSTI SKDLITYMSG TKSTEFNNTV SCSNRPHCLT EIQSLTFNPT AGCASLAKEM FAMKTKAALA IWCPGYSETQ INATQAMKKR RKRKVTTNKC LEQVSQLQGL WRRFNRPLLK QQ |
| 预测分子量 | 15 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TSLP重组蛋白的参考文献示例(注：以下内容为模拟示例，实际文献需通过学术数据库核实)：
---
1. **文献名称**：Cloning and Functional Characterization of Recombinant Human Thymic Stromal Lymphopoietin (TSLP)
**作者**：Ziegler, S.F., et al.
**摘要**：该研究首次报道了人源TSLP基因的克隆及重组蛋白表达，证实重组TSLP可通过激活树突细胞诱导Th2型免疫反应，为研究其在哮喘和过敏性皮炎中的作用奠定基础。
2. **文献名称**：TSLP Promotes Allergic Inflammation through Dendritic Cell Activation
**作者**：Allakhverdi, Z., et al.
**摘要**：利用重组TSLP蛋白进行体外实验，揭示其通过树突细胞表面受体复合物触发IL-4、IL-5等Th2细胞因子分泌，驱动过敏性气道炎症的发生。
3. **文献名称**：Epithelial Cell-Derived TSLP Initiates Airway Hyperresponsiveness in Asthma Models
**作者**：Soumelis, V., et al.
**摘要**：研究通过重组TSLP蛋白刺激小鼠模型，证明上皮细胞释放的TSLP通过激活髓样树突细胞，促进Th2极化及气道高反应性，直接关联哮喘病理机制。
4. **文献名称**：TSLP as a Master Switch in Barrier Immunity
**作者**：Siracusa, M.C., et al.
**摘要**：通过重组蛋白功能实验，阐明TSLP在皮肤和肠道上皮屏障中的核心作用，其异常表达可导致慢性炎症性疾病，提示其作为治疗靶点的潜力。
---
建议通过PubMed、Web of Science等平台检索具体文献，并核实作者及出版信息。
Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine belonging to the interleukin-7 (IL-7) family, first identified for its role in promoting lymphocyte development. It signals through a heterodimeric receptor complex comprising TSLPR (TSLP receptor) and IL-7Rα, activating downstream pathways like JAK-STAT, MAPK, and NF-κB. TSLP is a key mediator of type 2 immune responses, influencing dendritic cells, mast cells, and T helper 2 (Th2) cells, and is implicated in allergic diseases such as asthma, atopic dermatitis, and chronic rhinosinusitis. Its overexpression in barrier tissues links it to chronic inflammation and tissue remodeling.
Recombinant TSLP proteins are engineered using expression systems like mammalian cells (e.g., CHO, HEK293) or *E. coli*, with variations in post-translational modifications depending on the host. Mammalian-derived TSLP typically retains native glycosylation patterns critical for receptor binding, while bacterial systems produce non-glycosylated forms suitable for structural studies. Purification involves chromatography techniques (e.g., affinity, size-exclusion) to ensure high purity and bioactivity.
Research-grade recombinant TSLP is widely used to study immune signaling, screen therapeutic agents (e.g., TSLP-blocking monoclonal antibodies like tezepelumab), and model disease mechanisms. Its role as a biomarker in clinical samples further underscores diagnostic relevance. Recent clinical trials targeting TSLP signaling highlight its therapeutic potential, driving demand for well-characterized recombinant variants. However, challenges remain in standardizing activity assays due to receptor complexity and species-specific variations. Ongoing studies explore its dual pro-inflammatory and regulatory roles in cancer and autoimmune conditions, expanding applications beyond allergic diseases.
×
